期刊
SCIENCE
卷 333, 期 6043, 页码 765-769出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1201662
关键词
-
资金
- Leukemia Lymphoma Society
- Empire State Stem Cell Scholar award
- Clinical Scholars award
- Starr Foundation
- NIH [GM62437]
- Gabrielle's Angel Foundation
- Acylin Therapeutics Inc.
The chromosomal translocations found in acute myelogenous leukemia (AML) generate oncogenic fusion transcription factors with aberrant transcriptional regulatory properties. Although therapeutic targeting of most leukemia fusion proteins remains elusive, the posttranslational modifications that control their function could be targetable. We found that AML1-ETO, the fusion protein generated by the t(8;21) translocation, is acetylated by the transcriptional coactivator p300 in leukemia cells isolated from t(8;21) AML patients, and that this acetylation is essential for its self-renewal-promoting effects in human cord blood CD34(+) cells and its leukemogenicity in mouse models. Inhibition of p300 abrogates the acetylation of AML1-ETO and impairs its ability to promote leukemic transformation. Thus, lysine acetyltransferases represent a potential therapeutic target in AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据